4basebio PLC, an innovation-driven biotechnology company, has announced that its directors, Heikki Lanckriet and David Roth, have sold shares in order to pay for options exercised. Lanckriet sold 45,322 shares at 660p per share, representing 11.09% of the issued share capital, while Roth sold 38,292 shares at the same price, accounting for 3.58% of the issued share capital. The calculations are based on an issued share capital of 12,796,208 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310. The transactions were conducted on the London Stock Exchange, AIM, on 2nd February 2024.

4basebio PLC is a company focused on enabling and accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, thermostable nucleic acid delivery platform. For further enquiries, interested parties can contact 4basebio PLC at +44 (0)12 2396 7943.

The notification of the transactions was made pursuant to Article 19(1) of Regulation (EU) No. 596/2014. Dr. Heikki Lanckriet, the CEO, and David Roth, the CFO, were the persons discharging managerial responsibilities involved in the transactions. The nature of the transactions was the sale of Ordinary Shares, with the price per share set at 660p. The LEI of 4basebio PLC is 213800E2DX9EAIUNCB30.

This announcement provides insight into the recent activities of 4basebio PLC's directors and offers transparency regarding the sale of shares to pay for options exercised.